The panels began investigating Aduhelm’s approval and pricing in June 2021, just weeks after it won the FDA’s backing despite questions about the drug’s clinical benefit to patients.
Related posts:
White House, state officials scramble to get docs’ help with lagging vaccination effort
CDC panel endorses use of Pfizer Covid-19 vaccine in young teens
Abbott asks Texas hospitals to postpone elective procedures to free beds for latest Covid surge
Children’s hospitals are swamped with Covid patients — and it may only get worse
Newsom: California teachers must get vaccinated or tested weekly
Surgeon general: New vaccine policies neither illegal nor unusual
Biden’s team tightens grip on state use of Covid antibody treatments
Kids are behind on routine immunizations. Covid vaccine hesitancy isn’t helping.
Most of Beijing to be tested for Covid amid lockdown fears
FDA expected to authorize Moderna, Pfizer-BioNTech Omicron boosters
Biden administration weighs saving monkeypox doses for potential smallpox outbreak
CDC advisers recommend Covid-19 boosters updated to target Omicron strains
